Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Lord Markham on 28 November 2022 (HL3401), whether they can provide further information on (1) the additional expert advice received, (2) when this advice was sought and received, (3) who were the experts, and (4) who they reported to.

The expert advice used to determine the cohorts eligible for COVID-19 treatment was led by the Therapeutics Clinical Review Panel. The panel periodically reviews new evidence on the definition and revision of eligible cohorts for COVID-19 therapeutics from several sources, including clinical evidence and expert groups. The Independent Advisory Group, led by Professor Iain McInnes, produced a report on the potential cohorts eligible for pre-exposure prophylaxis. This clinical advice was agreed by the panel and has been submitted to the National Institute for Health and Care Excellence (NICE) as part of their Health Technology Evaluation of Evusheld.

The materials submitted to the NICE committee will be published once the process has completed.